소용 백신 시장 : 시장 규모, 점유율, 성장, 산업 분석, 지역 인사이트, 예측(2026-2034년)

Growth Factors of bovine vaccines Market

The global bovine vaccines market was valued at USD 3.90 billion in 2025 and is projected to grow from USD 4.04 billion in 2026 to USD 6.32 billion by 2034, registering a CAGR of 5.76% during the forecast period. The market is witnessing steady growth due to the increasing prevalence of infectious diseases among cattle, rising demand for dairy and meat products, and growing awareness regarding preventive animal healthcare. Bovine vaccines play a crucial role in protecting cattle from diseases such as Foot-and-Mouth Disease (FMD), brucellosis, hemorrhagic septicemia, black quarter, and bovine respiratory diseases, helping improve livestock productivity and food security.

North America dominated the global bovine vaccines market in 2025, accounting for 46.41% of total market revenue, supported by advanced veterinary healthcare infrastructure, large commercial cattle populations, and strong vaccination programs.

Bovine Vaccines Market Trends

A major trend shaping the market is the increasing adoption of intranasal and alternative-route vaccination technologies. Livestock producers and veterinarians are increasingly focusing on intranasal vaccines due to their ability to provide rapid mucosal immunity, especially against respiratory diseases in young calves. These vaccines offer easier administration, reduced injection-site reactions, and improved protection against early-life infections.

In October 2025, MSD Animal Health reported positive results from its BOVILIS NASALGEN-C intranasal vaccine, highlighting improved production outcomes in veal calves vaccinated against bovine coronavirus.

Market Drivers

Expansion of Government Vaccination Programs

Government-supported disease control and vaccination initiatives are significantly driving market growth. National livestock health programs are increasing vaccine accessibility through mass immunization campaigns and financial support. These programs are particularly focused on controlling diseases such as FMD, brucellosis, and rabies, which can severely impact livestock productivity and international trade.

For example, the Government of India reported in January 2025 that cumulative vaccination under national programs reached 107.34 crore doses for FMD and 4.39 crore doses for brucellosis, demonstrating strong government involvement in disease prevention.

Market Restraints

Supply Chain and Distribution Challenges

Despite increasing demand, the market faces challenges related to vaccine storage, cold-chain management, transportation, and last-mile delivery. Maintaining vaccine quality requires strict temperature-controlled logistics, particularly in remote cattle-rearing regions. Poor distribution networks can reduce vaccination effectiveness and limit market penetration.

According to WOAH's 2025 Animal Health Forum, vaccine accessibility continues to be affected by distribution inefficiencies, cold-chain limitations, and inadequate veterinary infrastructure.

Market Opportunities

Growing Research and Development Activities

Rising investments in veterinary biotechnology and vaccine development present significant opportunities for market expansion. Researchers are focusing on developing advanced vaccines that offer broader protection and improved efficacy against emerging diseases affecting cattle.

In August 2024, researchers at the University of Missouri developed a vaccine targeting bovine anaplasmosis, a serious tick-borne disease that affects cattle health and agricultural productivity.

Market Challenges

Low Farmer Awareness and Vaccination Compliance

Limited awareness regarding complete vaccination schedules remains a key challenge. Failure to follow booster doses and veterinarian-recommended vaccination timelines can reduce vaccine effectiveness and increase disease outbreaks. In many developing regions, farmer education and vaccination compliance continue to be major concerns affecting market growth.

Segment Analysis

By Product

The inactivated vaccines segment dominated the market in 2025 due to widespread use in dairy and beef cattle for respiratory, reproductive, and infectious disease prevention. Their proven safety profile and strong regulatory support contribute to their leadership position.

The recombinant vaccines segment is expected to witness the fastest growth, registering a CAGR of 9.52% during the forecast period due to advancements in biotechnology and improved vaccine efficacy.

By Route of Administration

The parenteral segment held the largest market share in 2025. Subcutaneous and intramuscular injections remain the preferred administration methods because they provide reliable immune responses, rapid protection, and established veterinary acceptance.

The intranasal segment is projected to grow at a CAGR of 8.65%, supported by increasing demand for respiratory disease prevention in calves.

By Distribution Channel

The veterinary clinics segment accounted for the largest market share in 2025. Veterinary clinics provide professional guidance on vaccination schedules, booster requirements, and disease management strategies, making them the preferred distribution channel among livestock producers.

The pharmacies and drug stores segment is expected to grow at a CAGR of 5.96% during the forecast period.

Regional Analysis

North America

North America remained the leading regional market, reaching USD 1.81 billion in 2025. The region benefits from a large cattle population, strong preventive healthcare practices, and robust veterinary research investments.

The U.S. bovine vaccines market is projected to reach USD 1.75 billion in 2026, accounting for approximately 43.5% of global revenue.

Europe

Europe is expected to grow at a CAGR of 5.78% through 2034. Increasing bluetongue outbreaks, structured vaccination programs, and strong cattle-health initiatives are supporting regional growth.

Asia Pacific

Asia Pacific is projected to reach USD 0.54 billion in 2026, driven by large livestock populations and expanding government vaccination programs.

Country-level projections for 2026 include:

• India: USD 0.18 billion
• China: USD 0.14 billion
• Japan: USD 0.02 billion

Latin America and Middle East & Africa

These regions are expected to witness steady growth due to increasing livestock disease prevalence and expanding government-supported vaccination campaigns. Latin America is estimated to reach USD 0.35 billion in 2026, while the GCC market is projected at USD 0.02 billion.

Competitive Landscape

The bovine vaccines market is moderately competitive, with major players focusing on product innovation, manufacturing expansion, and strategic collaborations.

Leading companies include:

• Zoetis Services LLC
• Merck & Co., Inc.
• HIPRA
• Elanco
• Boehringer Ingelheim International GmbH
• Virbac
• Ceva
• Indian Immunologicals Ltd.

These companies continue to invest heavily in vaccine development, disease prevention technologies, and global market expansion strategies.

Key Industry Developments

• March 2026: South Africa expanded its FMD vaccine sourcing framework through partnerships with multiple international suppliers.
• July 2025: Elanco launched NUPLURA PH+5, a vaccine designed to protect calves from multiple respiratory diseases.
• May 2025: Boehringer Ingelheim received market authorization in Germany for its BTV-3 vaccine.
• May 2025: HIPRA launched HIPRABOVIS SOMNI/Lkt for bovine respiratory disease prevention.
• February 2025: Elanco partnered with Medgene for commercialization of avian influenza vaccines in dairy cattle.

Conclusion

The global bovine vaccines market is positioned for sustained growth, increasing from USD 3.90 billion in 2025 to USD 4.04 billion in 2026, and reaching USD 6.32 billion by 2034. Growth is being driven by rising disease prevalence in cattle, expanding government vaccination initiatives, increasing demand for dairy and meat products, and continuous innovation in veterinary vaccine technologies. Although supply-chain challenges and low vaccination compliance remain concerns, ongoing R&D investments and improved disease-control programs are expected to strengthen market expansion throughout the forecast period.

Segmentation Product, Route of Administration, Distribution Channel, and Region

By Product * Inactivated

• Live Attenuated
• Recombinant
• Others

By Route of Administration * Oral

• Parenteral
• Intranasal

By Distribution Channel * Veterinary Hospitals

• Veterinary Clinics
• Pharmacies & Drug Stores
• Others

By Region * North America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)

• U.S.
• Canada
• Europe (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product, Route of Administration, Distribution Channel, Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview of Bovine Diseases by Key Countries, By Key Countries/ Region, 2025
• 4.2. Regulatory Scenario by Key Countries/ Region
• 4.3. Overview of Vaccination for Bovine Diseases
• 4.4. New Product Launches, By Key Players
• 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Bovine Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product
  • 5.1.1. Inactivated
  • 5.1.2. Live Attenuated
  • 5.1.3. Recombinant
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.2.1. Oral
  • 5.2.2. Parenteral
  • 5.2.3. Intranasal
• 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.3.1. Veterinary Hospitals
  • 5.3.2. Veterinary Clinics
  • 5.3.3. Pharmacies & Drug Stores
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Bovine Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product
  • 6.1.1. Inactivated
  • 6.1.2. Live Attenuated
  • 6.1.3. Recombinant
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.2.1. Oral
  • 6.2.2. Parenteral
  • 6.2.3. Intranasal
• 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.3.1. Veterinary Hospitals
  • 6.3.2. Veterinary Clinics
  • 6.3.3. Pharmacies & Drug Stores
  • 6.3.4. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Bovine Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product
  • 7.1.1. Inactivated
  • 7.1.2. Live Attenuated
  • 7.1.3. Recombinant
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.2.1. Oral
  • 7.2.2. Parenteral
  • 7.2.3. Intranasal
• 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.3.1. Veterinary Hospitals
  • 7.3.2. Veterinary Clinics
  • 7.3.3. Pharmacies & Drug Stores
  • 7.3.4. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. Germany
  • 7.4.2. U.K.
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Bovine Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product
  • 8.1.1. Inactivated
  • 8.1.2. Live Attenuated
  • 8.1.3. Recombinant
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.2.1. Oral
  • 8.2.2. Parenteral
  • 8.2.3. Intranasal
• 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.3.1. Veterinary Hospitals
  • 8.3.2. Veterinary Clinics
  • 8.3.3. Pharmacies & Drug Stores
  • 8.3.4. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Southeast Asia
  • 8.4.6. Rest of Asia Pacific

9. Latin America Bovine Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product
  • 9.1.1. Inactivated
  • 9.1.2. Live Attenuated
  • 9.1.3. Recombinant
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.2.1. Oral
  • 9.2.2. Parenteral
  • 9.2.3. Intranasal
• 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.3.1. Veterinary Hospitals
  • 9.3.2. Veterinary Clinics
  • 9.3.3. Pharmacies & Drug Stores
  • 9.3.4. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Bovine Vaccines Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product
  • 10.1.1. Inactivated
  • 10.1.2. Live Attenuated
  • 10.1.3. Recombinant
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.2.1. Oral
  • 10.2.2. Parenteral
  • 10.2.3. Intranasal
• 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.3.1. Veterinary Hospitals
  • 10.3.2. Veterinary Clinics
  • 10.3.3. Pharmacies & Drug Stores
  • 10.3.4. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of the Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Boehringer Ingelheim International GmbH
  • 11.2.2. Elanco
  • 11.2.3. Zoetis Services LLC
  • 11.2.4. Ceva
  • 11.2.5. Virbac
  • 11.2.6. Merck & Co., Inc.
  • 11.2.7. HIPRA
  • 11.2.8. Indian Immunologicals Ltd.